



ABN 26 521 960 054

LIONS CANCER INSTITUTE INC

ANNUAL REPORT 2017-2018

SAVING
lives **IN YOUR**
COMMUNITY THROUGH
screening **AND**
RESEARCH.





PROF. GEORGE YEOH,
BSC, PHD.
PRESIDENT WA
CANCER COUNCIL

It is an honour to be appointed Patron of the Lions Cancer Institute for many reasons. It is an organisation that serves the community; and especially its rural and remote members who have poorer outcomes as a result of cancer. It is distinguished by having a large body of dedicated and highly qualified volunteers who make a difference to cancer patients, and particularly those with skin cancer. The war against this dreaded disease must be waged on many fronts. These include acquisition of knowledge of the enemy to exploit its weakness through research; adopting lifestyle practices that reduce its incidence through education and advocacy and improving diagnosis by increased surveillance and precision in detection. The Lions Cancer Institute is working on all these fronts by providing resources to support activities that underpin these strategies.

Fortunately, Australians derive enormous benefit from an excellent health system; however, as our population ages, the burden of cancer will increase proportionately. Thus numerically, the “enemy” will be more and more substantial. Today, more than a million Australians are cancer survivors. This is a testament to the effectiveness of the anti-cancer organisations that take up the call to fight this disease. The Lions Cancer Institute is a proud member of this group that will collectively confront escalating challenges into the future. I salute the volunteers of this organisation for all their contributions past and outcomes achieved. I thank you for the opportunity to join you for the journey we will take together in the future.

2017/2018 Board of Directors	5
Chairman	6
Club Donations	18
Medical & Scientific	10
Multi District Skin Screening	16
Organisational Chart	9
PhD Student	14
PR & Business Development	8
Screening Manager	12
SunScreen Advert/Compassion Diamond Advert	19
Treasurer	17

ELECTED MEMBERS

Lion Phil Chinnery	Chairman
PDG Pam Baird	Vice Chairman
PDG Garry Irvine	Director PR/Business Development
Lion David Baird	Director Ass. Treasurer
Lion Dale Thomson	Director
Lion June Walker	Director
Lion Michael Wainwright	Director
Lion Mary Anne Wolf	Director

APPOINTED MEMBERS

Lion Margot McNally	Director
Lion John Osborne	Director Screening Event Co-ordinator
PDG Neil F. Saunders	Treasurer
Lion Dot Saunders	Secretary
Rob Fitz Patrick, FRCS, FRACS	Chair Medical & Scientific Advisory Committee

EX OFFICIO MEMBERS

DG Sue Lowe	District Governor 201W1
DG Grant Hewett	District Governor 201W2
1 st VDG Luen Chicote	1 st VDG District 201W1
1 st VDG Bev Hawkins	1 st VDG District 201W2
Lion Leonie Getty JP	District Chairman elect 201W1

CO-OPTED, NON-VOTING, MEMBERS

PDG Colin C. Beauchamp AM JP	Western Australia
Lion Chris Lowings	South Australia
Lion Marilyn Miller	South Australia

The Lions Cancer Institute Inc. is a "Not For Profit" medical research institution. The Institute holds an Endorsement from the Australian Tax Office as an income tax exempt charitable entity (ITEC) and is a deductible gift recipient (DGR). The Institute holds a licence issued under the provisions of the Charitable Collections Act. Auditor/Accountant is Dharam Ghandis, Auditax Accountants, North Perth WA. Institute web site: www.lionscancerinstitute.org.au

CHAIRMAN'S REPORT



LION PHIL CHINNERY

It has been a very busy and successful year to date with the introduction of a structured management organisation, some new faces on the Board, and one of the busiest years of screening events throughout Western Australia, from Esperance in the south to Kununurra and surrounds in the north.

As your new Chairman I must thank PDG Colin Beauchamp, AM JP, for his dedicated and strong leadership over the last five years in the chair, especially for leading the push into South Australia and Northern Territory under Lions Districts C1 and C2. This connection led to the Skin Cancer Screening project being nominated as a Category B Project at the Multiple District Convention in Townsville, which was successful.

I sadly acknowledge the passing of two Board members in the last year. Paul Katris, formerly CEO of the West Australian Clinical Oncology Group and Chair of our Medical and Scientific Advisory Board last year, and PDG Robert (Bob) Thomson, a retired Director of the Board. Both Paul and Bob contributed greatly to the work done by the Institute over the years and are sadly missed.

This past year sees the addition to the Board of Lion John Osborne, a member of the Mandurah Lions Club. John has taken on the role of Screening Coordinator, responsible for taking the applications received for screening events and planning the roster, including arranging flights and accommodation bookings, liaison with organisers at the locations, and ensures the vehicles are maintained and ready for use. You will read about our work on screening in John's report elsewhere in this document.

Another newcomer to the Board, but no stranger to most of us is retired Dr Robert Fitzpatrick, MB BS FRCS FRACS. Rob has been a plastic surgeon since 1986 and a Lions screener since 1993. Rob is a valuable member of the screening teams and often joins us, with his wife Libby, on the many longer trips throughout the State. He is the Medical Director for the Institute with responsibilities including selection and liaison with our PhD students, recruitment, assessment and selection of screeners, as well as his frequent participation in screening events.

For the Institute to be able to continue with the screening program, especially in the country area's it is essential to have trained screeners available and willing to give some time. As reported last year we have an agreement in place to have selected trainees participate in an on-line course in Dermoscopy (the diagnosis and assessment of skin cancer lesions) with Molechecks, a division of Bedford Medical Group, based in Adelaide.

The second group of eight trainees, four each from SA and WA are currently part way through their training and we plan to have them attend screening events progressively to gain experience and develop their skills and confidence. PDG Colin is seconded frequently to assist the South Australian screeners and offers his expertise and advice to their trainees as well.

I am very pleased to confirm we have secured as our Patron Professor George Yeoh. George has spent most of his professional life in the study of cancer, most particularly seeking a cure for liver cancer. You can read more from George in his introduction elsewhere in this document.

Throughout this annual report you will also read reports from our Treasurer, PDG Neil Saunders, PDG Garry Irvine, and our current PhD student Tracey Seymour.

PDG Neil has been of great assistance to me with his knowledge of the Institute, its financial affairs, and more recently his work in getting our documentation and communications onto the Office365 platform and saved in the "Cloud".

Lion Dot Saunders must also be acknowledged for her past work as Secretary, which she has relinquished to be trained and participate in screening.

Tracey is nearing the end of her three year course of study at the Telethon Kids Institute within the Brain Tumour Research Group, part funded under the K&J Chinnery Scholarship governed by the Institute and funded from donations from Lions Clubs.

I acknowledge PDG Garry Irvine for his leadership and work in the Business Development, Public Relations

and New Zealand liaison role of the Institute. Garry spends quite a lot of time travelling in the US with his wife, Heather, but maintains communications with us quite easily in this modern world. While in the US Garry arranged a meeting with PDG Keith Kenderdine and me in Las Vegas, where we discussed a continuation of the proposal to have the Skin Cancer Screening Project taken up in NZ. You can read more on Garry's work in his report.

To all these people, and all the screeners, drivers and administrators I offer my sincere thanks for all your hard work and time, and look forward to seeing the Institute's further growth and positive affect on those detected with suspicious skin cancers.

■ Lion Phil Chinnery—Chairman



▲ DRIVER PHIL PREPARING FOR NEXT STAGE FROM DONGARA 2017



◀ CENTENARY GRANT AT SUCCESS, WA.



PDG GARRY IRVINE

Once again it is time to provide a summary of the activity over the last 12 months by your Lions Cancer Institute, firstly there was the change of Chairman which saw the long serving PDG Colin Beauchamp AM., JP, stand down and hand the duties over to Lion Phil Chinnery from the Armadale- Kelmscott Club

Colin has steered the Institute over many years and has been the major driving force which has seen the purchase and fit outs of our two current Mobile Units, he has and continues to attend screenings both in WA and in SA as a Dermoscopist. He played a major role in setting up the screening programme in SA and recently was the mover for the Motion at Townsville to seek delegates support for a Category "B" Project and that as we now know was successful. He will be a link between SA and WA to begin the promotion Australia wide to all Clubs and Districts to build a Lions National Skin Cancer Screening Service.

We have now developed a management structure with specific duties being allocated at Board level and that has enabled the Board to streamline our Screening Roster for each year. The need for trained Screeners continues to challenge the Board and with the appointment of our new Medical Director Dr Rob Fitzpatrick plans are being made to address that issue. Existing Screeners will be regularly informed now of what screenings we have planned for the year and will be invited to slot their names into the Roster when they are available. The invitation to new potential screeners will be ramped up and the On Line training programme will be afforded to those applicants accepted by the Board.

Screenings continue with our Teams being out on 50 plus occasions annually and covering areas from the far north to the southern tip of WA. Everyone who volunteers to participate report a great time with lots of laughs and food and accommodation provided. The results of course are the serious part of every screening and the fact that we save lives by early detection gratifies all who participate.

We have been well supported by the Commonwealth Bank this year with two grants from two of their Perth branches, the latest shows Chairman Phil holding the cheque from Peter Townsend with LCI Directors Garry Irvine and Neil and Dot Saunders alongside.


All of this provides brilliant PR for our Lions Clubs and we appreciate the support we receive, so if your Club does help us with a donation each year then the Board of your Lions Cancer Institute sincerely appreciates that – however if your Club has missed that opportunity to help fund what we do then we don't hesitate to ask that you find it very important this time that your Club consider our running costs for this Project (\$120,000 per annum) and offer your financial support.

■ PDG Garry Irvine—PR & Business Development Director

NEW CHAIRMAN
LION PHIL CHINNERY ▶



RECEIVING A \$10,000
CHEQUE FROM COMM.
BANK ▼





ROBERT FITZPATRICK
FRCS, FRACS

Lions Skin cancer screening has been performed for over 25 years in Western Australia.

This year the screening teams will see over 4000 patients which involves about 48 manhours per screen and over 192 hours driving. Our thanks to John Osborne for his great organizing of this complex venture.

WHAT IS THE FUTURE?

The Lions have recently made the Skin Cancer Screening a Category B project which means it should be adopted in all the other states. I see a big problem arising. In Western Australia, the majority of screenings have been performed by a handful of people, some of whom are getting to the point that they will need to retire from this venture. It is getting more difficult to attract volunteers. There are many reasons for this; marriage occurs at a later age, parents are therefore engaged with children till later in life, mortgage stress, longer working hours and the move to more male involvement in parenting. I have approached a few doctors who have indicated that at the end of a week they want a rest from examining skins for abnormalities and do not want to donate time to this worthwhile project. All volunteering services have similar problems!

We have a training online program in place and a few people have been through the course. To be a competent screener it requires examination of scores of peoples' skin, under supervision, with feedback from experienced screeners. At present this course is based in South Australia but we are trying to develop a course in Western Australia. A local course would have the advantage of the time zone.

It has been found that screening for all skin cancers by a GP is as accurate as a GP working in skin cancer clinics, but melanoma diagnosis is more sensitive in a dedicated skin clinic, while thinner melanomas are diagnosed more often by Dermatologists than all GP'S and subsequently had a 34% lower mortality. This is despite the limited exposure of the average GP while training.

SOME OF THE LIONS IMPORTANT ROLES ARE

- 1) To disseminate the message of prevention vis: Slip, slap, slop and beware of refracted light, there is no such thing as wind burn!
- 2) Early detection with regular screens; 55- 70% of melanomas are detected by the patient themselves, 12% are found on a systematic examination and 55% detected by physicians are found on routine clinical examination.
- 3) Our other targets should be to follow up the patients we refer and to collect useful data to determine the impact of the service.
- 4) Scholarship.

In a separate report one will find that the LCI scholarship holder, Tracey Seymour, is coming to the end of her tenure. It appears she has advanced the treatment potential of brain tumours and we wish her well for her future.

Next year the LCI can offer two scholarships to eligible PhD students. The results of applications will be announced later this year

- 5) Education.

As a regular screener I have noticed that the public do not

understand that melanomas are by far the least common skin cancers although the deadliest.

2/3 of people in Australia will be treated for skin cancer by the time they are 70.

750,000 people are treated for keratinocyte (nonmelanoma) skin cancers each year of which about 1/3 are squamous and 2/3 are basal cell skin cancers. Almost 600 people die each year from these lesions.

About 13,500 melanoma cases are treated each year and although the prognosis is improving there are still nearly 1800 deaths.

As one can see, keratinocyte skin cancer is 50-60 times more common than melanoma, but not nearly as deadly.


In 2014 \$9.4 million in Medicare benefits were paid for melanoma treatment and \$127.6 million for keratinocyte cancers. The latter accounts for 8.1% of the health treatment budget.

If the Lions Cancer Screening can be effective in diagnosing all skin cancers at an earlier time, then it is a worthwhile contribution to limiting the morbidity and costs to the community.

■ Robert Fitzpatrick FRCS, FRACS—Plastic Surgeon (Retired)



▲ LION JUNE USE THE LUMIO TO SCREEN



▲ ROB SCREENING AT COTTESLOE



▲ SCREENER COLIN IN ACTION



JOHN OSBORNE

Our Cancer Skin Screening program is one of the key objects of the Lions Cancer Institute by providing free Skin Screening Checks in Rural and Remote areas of the State where ready access to Skin Checks is not always available.

This free service is only made possible by the generosity of the institutes Screening Team. In providing this service. A panel of volunteer Dermatologists, Plastic Surgeons, GPs, Dermoscopists, Administrators and Drivers have voluntarily given over 2200 hours of their time. This work has been shared by the 16 Volunteers on the Screening Panel and the 15 Volunteers on the Driver and Administration panel.

The Screening program would not be possible without support from the host organisations in the communities where screenings were conducted. Support was provided by Lions and Lionesses Clubs, CWA Branches, Community Resource Centres, Community Health Centres, Hospitals and Rotary. The involvement by these community organisations ensure that our Screening program is successful.

During the past year, with the assistance of all the volunteers, the Lions Cancer Institute was able to provide 60 Days of Free Skin Screenings, in 43 locations throughout the State, from Wyndham in the North, Nova Nickel Mine East of Norseman and to Esperance in the South. The distance covered was 12,000 Kilometres, with over 200 hours of driving involved.

As always with Plant and Equipment, it only breaks down when being used. During this year's program we experienced maintenance issues at various times. These were addressed with the help of local tradespeople where their services were provided free of charge, or at discounted prices.

I would like to thank all the volunteers who have generously participated in this year's Screening program. Your efforts resulted in 880 people being referred for further treatment. There is no doubt that through this program lives have been saved and enhanced.

■ John Osborne—Screening Events Manager.

4278 TOTAL SCREENED

Number of Referrals	880
% Referred	21%
Life Threatening Lesions	488
Screened less than 6 months	237
Screened 6 - 12 months	682
Screened over 12 months	1972

1387 NEVER SCREENED

Number of Locations	43
Days Screening	60
Hours Screening	2018

\$7447 SPENT IN FUEL

Accommodation	\$22,356
Travel - Air Fares, Parking, Mileage	\$30,024
Sustenance	\$14,350
Fuel Coach	\$5,631
Fuel Hino	\$1,092
Fuel Gensets	\$724
Generator Sets	\$1,424
Hino	\$5,879
Coach	\$17,484
Van	\$7,753



◀ PREMIER PAID A VISIT A KARRATHA



COACH AT NORSEMAN ROUNDABOUT ▶



◀ TAKING REGISTRATIONS IN DONGARA




EN ROUTE TO CARNAVON ▶



◀ GETTING THE WORK BOOTS OFF BEFORE SCREENING AT NOVA NICKEL MINE



HIJACKED BY SOME SALMON GUMS RESIDENTS ▶



TRACEY SEYMOUR

My PhD research focuses on finding new therapies for the most common brain tumour, glioblastoma. Glioblastoma is a fatal type of human brain tumour. Current treatment includes maximal safe surgical resection, followed by radiotherapy and chemotherapy such as temozolomide. But these treatments are not curative and an average survival of 15 months is very dismal. Poor patient outcomes are mainly due to glioblastoma cells having the ability to resist radiotherapy and temozolomide.

My PhD research involves pre-clinical studies that is currently testing new therapies, in hope to find therapies that will augment current treatments and improve patient outcomes.

CURRENT RESEARCH AIMS:

1. Determine whether new treatments will interact together with radiotherapy and/or chemotherapies such as temozolomide and gemcitabine.
2. Explore the mechanism in which these new therapies help to improve tumour cell death.
3. Examine whether combining new therapies to radiation therapy or chemotherapies such as temozolomide and gemcitabine will provide a survival benefit.

AIM 1: DETERMINE WHETHER NEW TREATMENTS WILL INTERACT TOGETHER WITH RADIATION THERAPY AND/OR CHEMOTHERAPIES SUCH AS TEMOZOLOMIDE AND GEMCITABINE.

Current Findings

We have tested three new drug therapies. The most promising therapy tested was an inhibitor of a protein called cell cycle checkpoint kinase 1/2 (inhibitor of Chk1/2). Using several different glioblastoma cell lines, we have shown that the inhibitor of Chk1/2 causes a reduction in tumour cell growth. More importantly, this Chk1/2 inhibitor works together with radiotherapy and chemotherapies such as temozolomide and gemcitabine.

Significance

This study has helped us determine a potential new therapy for patients with glioblastoma.

AIM 2: EXPLORE THE MECHANISM IN WHICH THESE NEW THERAPIES HELP TO IMPROVE TUMOUR CELL DEATH.

Current Findings

Using protein analysis, we confirmed that the Chk1/2 inhibitor was stopping the protein called cell cycle checkpoint kinase 1/2. We also determined that this prevented tumour cells from repairing damage caused by radiotherapy or chemotherapy such as temozolomide or gemcitabine. Therefore, tumour cells remain damaged and further studies will determine if these damaged tumour cells are undergoing the process of dying.

Significance

These experiments help us understand how the Chk1/2 inhibitor is working to improve tumour cell death.

AIM 3: EXAMINE WHETHER COMBINING NEW THERAPIES TO RADIATION THERAPY OR CHEMOTHERAPIES SUCH AS TEMOZOLOMIDE AND GEMCITABINE WILL PROVIDE A SURVIVAL BENEFIT.

Current Findings

Using three of our glioblastoma cell lines, we have implanted these cells into the brains of mice. Firstly, the immediate effects of the inhibitor of Chk1/2 with/without radiotherapy, temozolomide or gemcitabine was examined. Combination therapy reduced tumour cell growth and increased tumour cell DNA damage. Excitedly, in two out of three cell lines, the combination of Chk1/2 inhibitor with radiotherapy, temozolomide or gemcitabine significantly extended survival.

Significance

These studies show the potential of combining the Chk1/2 inhibitor with radiotherapy or chemotherapy in improving

patient outcomes.


All of these experiments will provide robust data that will inform future clinical trials for glioblastoma patients.

CONFERENCE ATTENDANCE

1. Seymour T, Kuchibhotla M, Nowak A, Gottardo N & Endersby R. Exploring cell cycle checkpoint inhibition and gemcitabine treatment for glioblastoma, Australian Society for Medical Research, Perth June 2018. Oral Presentation
2. Seymour T, Kuchibhotla M, Nowak A, Gottardo N & Endersby R. Cell cycle checkpoint inhibition enhances conventional glioblastoma treatments. Lorne Cancer Conference, Victoria. February 2018. Poster Presentation
3. Seymour T, Kuchibhotla M, Nowak A, Gottardo N & Endersby R. Cell cycle checkpoint inhibition enhances conventional glioblastoma treatments. Telethon Kids Institute Scientific Retreat, Perth November 2017. Oral presentation.
4. Seymour T, Kuchibhotla M, Nowak A, Gottardo N & Endersby R. Cell cycle checkpoint inhibition enhances conventional glioblastoma treatments. Child and Adolescent Health Services Symposium, Perth October 2017. Poster presentation.
5. Seymour T, Nowak A, Gottardo N & Endersby R. Sensitising glioblastoma to enhance cancer therapy, Combined Biological Sciences Meeting, Perth August 2017. Oral Presentation
6. Seymour T, Nowak A, Gottardo N & Endersby R. Sensitising glioblastoma to enhance cancer therapy, Australian Society for Medical Research, Perth June 2017. Oral Presentation

■ Tracey Seymour—PhD student from The University of Western Australia and Telethon Kids Institute

"THE LIONS CANCER INSTITUTE INC. CONTINUES TO SUPPORT PhD STUDENTS INVOLVED WITH ALL TYPES OF CANCER RESEARCH. TRACEY IS OUR CURRENT STUDENT AND HAS BEEN SUPPORTED FOR NEARLY THREE YEARS. WE HAVE PREVIOUSLY SUPPORTED STUDENTS STUDYING PROBABLE CAUSES OF BOWEL CANCER AND ANOTHER STUDENT WAS STUDYING POSSIBLE CAUSES OF LIVER CANCER. WE CAN ONLY WISH THESE DEDICATED YOUNG PEOPLE EVERY SUCCESS AND HOPE THAT OUR CONTINUED FINANCIAL SUPPORT WILL ONE DAY LEAD TO A BETTER UNDERSTANDING AND POSSIBLE CURE?"



PDG COLIN C. BEAUCHAMP AM JP

Following a successful motion put to the Multi District Convention in Townsville in May 2018 the Lions Free Skin Cancer Screening project is accredited as a Category 'B' Lions project.

Since inception the Institute's Charter has been to work towards having the free skin cancer screening available to all Australians.

Under the terms of the MD Constitution the Institute has made a commitment to assist clubs and/or districts in other states who express a desire to become involved, run such a project with administration, training, methodology etc.

Victoria has picked up the challenge with a newly formed

committee under the chairmanship of Past Council Chairman Bruce Hudson they are moving quickly to establish a mobile unit similar to those in Western Australia and South Australia.

The new Victorian committee has a representative from the Victorian Government, Margaret Fitzherbert MLC the Shadow Minister, Todd Harper of the Cancer Council, representative from the Skin Cancer Foundation of Victoria and Past International Director Tony Benbow OAM.

The Institute has had enquires from clubs in Tasmania and Queensland, these are being followed up as needed.

■ PDG Colin C. Beauchamp AM JP—Multi District Skin Screening



PDG NEIL SAUNDERS

I am happy to report that despite a very busy twelve months screening, the Institute has finished the financial year with a surplus. I opened my 2017 report with the same comment, and while there were some changes in our circumstances during the year we are managing to prepare an Annual Budget, with more detail than before, and keep within the parameters of the Budget.

Our base income from Club and Corporate sources is up by 45% on the previous year. This came about by an increase in donations from Clubs of \$17,345, up from a total of \$24,750 last year and an increase of \$5,057 in public donations at our screening events.

Naturally, with an increase in screening events, there were increases in our costs. Our Administration costs were up by \$1,274, mainly caused by the \$671 outlay to set up Office 365 as part of having a central storage system for our records, rather than on individual computers.

Our screening costs were up by \$37,541 on last year. This was brought about by the Board's decision to provide an extensive trip into the Pilbara and other Northern areas where we had not been for several years, and where there are no Lions Clubs to offer support. Nearly 50% of this increase was for transportation costs, which mainly consisted of air fares to get our screeners to and from the remote Northern areas of WA.

The costs of running our vehicles was up by \$4,265. Most of this was the extra \$3,000 for coach fuel on the Pilbara trip.

As mentioned in last year's report, the Board allocated a \$25,000 budget for the North West trip. We were \$8,958 over. The extra costs of fuel, air fares and accommodation, during a school holiday period, contributed to the blow out. \$6,513 in donations from Lions Clubs and members of the public reduced our deficit to \$2,445.

Our investment Portfolio has shown a growth of nearly \$48,898.

The growth was made up of \$41,341.96 in distributions, \$2,068.00 from Franking Credits refund, a change in market value of \$7,759.74, less \$2,280.02 in fees. Due to the ill health of our original advisor, we have been referred to another group, and they are undergoing "due diligence" regarding our Portfolio Stocks and will be meeting with members of the Executive to discuss future investment strategies.

Our Telemarketing, while still not popular with some Lions, is keeping the Institute in a viable financial position. Without the income from this source, plus our Portfolio growth, we were looking at a -\$99,472.08 loss for the year.

The Board approved the extension of funds for cancer research, with the offering of "Top Up" amounts to a second PhD student each year. This will cost the Institute \$24,000 a year for three years.

I would like to thank the Lions Clubs for their ongoing support when our teams are 'on the road'. Support, both financial, and physical, helps to make our efforts worthwhile. We are also very appreciative of the assistance given to the Institute by CWA branches and Community Resource Centre staff in towns where there aren't any Lions Clubs.

■ PDG Neil F Saunders—Treasurer



▲ OUR NEW BANNER

Your Directors present their report on the Institute for the financial year ended 30 June 2018.

The names of the Directors in office at the date of this report are:

Elected members:

Lion Phil Chinnery. Chairman.
 PDG Pam Baird. Vice Chairman.
 PDG Garry Irvine. Director Business Development
 Lion David Baird. Director Ass. Treasurer
 Lion June Walker. Director
 Lion Michael Wainwright. Director
 Lion Mary-Anne Wolfe. Director
 Lion Dale Thomson. Director

Appointed members:

PDG Neil F. Saunders. Treasurer
 Lion Dot Saunders. Secretary
 Mr. Rob Fitzpatrick, FRCS, FRACS. Chair Medical & Scientific Advisory Committee
 Lion John Osborne. Director Screening Event Coordinator
 Lion Margot McNally. Director.

Ex Officio members:

DG Sue Lowe DG District 201W1
 DG Grant Hewitt DG District 201W2
 VDG Luen Chicote, 1stVDG District 201W1
 VDG Bev Hawkins 1stVDG District 201W2
 Lion Leonie Getty District Chairman 201W1
 PDG Maxine Whitely District Chairman 201W2

Co-opted, Non-voting, members:

Lion Marilyn Miller South Australia
 Lion Chris Lowings South Australia
 PDG Colin C. Beauchamp AM JP.

Changes in Directors during the 2017/2018 Financial Year.

PDG Robert Thomson.	Director (Resigned)
Lion Robert Bates.	Director (Resigned)
PDG Darrel Mainard.	Director (Resigned)
Paul Katris. (CEO WACOG)	Director. (Deceased)

No significant changes in the Institute's state of affairs occurred during the financial year. The Lions Cancer Institute Inc. is a "Not for Profit" medical research institution. The Institute holds endorsements for the Australian Taxation Office as an Income Tax exempt Charitable Entity (ITEC) and is a Deductible Gift Recipient (DGR). The Institute is also registered with Australian Charities and Not for Profits Commission (ACNC)

The Institute holds a current West Australian Charitable Collections Licence under the provisions of the Charitable Collections Act 1946.

No significant change in the nature of these activities occurred during the year.

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Institute, the results of those operations, or the state of affairs of the economic entity in future financial years.

Signed in accordance with a resolution of the Board of Directors:

Philip R Chinnery

Neil F Saunders.

Philip Chinnery
 Chairman
 Place: Byford
 Dated: 01.10.2018

Neil F Saunders
 Treasurer
 Mandurah
 01.10.2018

INCOME STATEMENT

	Note	2018 (in \$)	2017 (in \$)
Donations		61,301.65	36,006.88
Show account income		877,717.38	814,810.83
SA Revenue		33,194.59	-
Portfolio distribution income		43,409.96	40,480.04
Change in net market value of investments		84,364.29	41,630.16
Other income		11,314.42	26,728.80
Administration expenses		(20,458.15)	(23,402.45)
Depreciation and amortisation expenses	2	(64,058.84)	(53,293.53)
Fundraising expenses		(20.91)	(1,150.91)
Portfolio expenses		(2,280.02)	(1,533.77)
Public relation expenses		(4,143.64)	(2,815.59)
Scholarship and award expenses		(6,000.00)	(6,000.00)
Screening expenses		(64,657.70)	(37,054.64)
Show account expenses	3	(660,822.58)	(624,758.95)
Skin cancer screening unit		(48,662.80)	(44,237.97)
South Australia costs		(28,304.54)	(769.43)
Staff expenses		(807,738.77)	(708,577.94)
Other expenses	4	(8,143.96)	(1,146.89)
SURPLUS FROM ORDINARY ACTIVITIES BEFORE INCOME TAX		71,996.46	84,607.04
Retained surplus at the beginning of the financial year		987,016.10	909,406.13
TOTAL AVAILABLE FOR APPROPRIATION		1,067,156.52	995,160.06

BALANCE SHEET

	Note	2018 (in \$)	2017 (in \$)
ASSETS			
CURRENT ASSETS			
Receivables	5	13,568.00	10,096.00
Cash assets	6	210,738.75	222,631.11
other assets	7	9,476.99	7,632.60
TOTAL CURRENT ASSETS		233,783.74	240,359.71
NON-CURRENT ASSETS			
Property, plant and equipment	8	151,982.06	197,637.17
Financial assets	9	770,185.87	658,364.19
TOTAL NON-CURRENT ASSETS		922,167.93	856,001.36
TOTAL ASSETS		1,155,951.67	1,096,361.07
LIABILITIES			
CURRENT LIABILITIES			
Payables	10	89,047.68	100,484.75
Credit card liabilities	9.6	307.17	
GST accrued		-262.13	409.09
TOTAL CURRENT LIABILITIES		88,795.15	101,201.01
TOTAL LIABILITIES		88,795.15	101,201.01
NET ASSETS		1,067,156.52	995,160.06
EQUITY			
Accumulated surplus		1,067,156.52	995,160.06
TOTAL EQUITY		1,067,156.52	995,160.06

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of Preparation

This financial report is a special purpose financial report prepared in order to satisfy the requirements of Board members to prepare a financial report. The Board members have determined that the Association is not a reporting entity. The financial report has been prepared in accordance with the requirements of Association Incorporation Act 2015 (WA), association regulations .

The financial statements have been prepared on an accruals basis and are based on historic costs and do not take into account changing money values or, except where specifically stated, current valuations of non-current assets.

The following material accounting policies, which are consistent with the previous period unless otherwise stated, have been adopted in the preparation of the financial statements.

(b) Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short term highly liquid investments with original maturities of three months or less.

(c) Property, Plant and Equipment

Leasehold improvements and office equipment are carried at cost less, where applicable, any accumulated depreciation.

The depreciable amount of all PPE is depreciated over the useful lives of the assets to the association commencing from the time the asset is held ready for use. Leasehold improvements are amortised over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

(d) Impairment of Assets

At the end of each reporting period, the committee reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset 's fair value less costs of disposal and value in use, to the asset 's carrying amount. Any excess of the asset 's carrying amount over its recoverable amount is recognised in the income and expenditure statement .

(e) Accounts Receivable and Other Debtors

Accounts receivable and other debtors include amounts due from members as well as amounts receivable from donors. Receivables expected to be collected within 12 months of the end of the reporting period are classified

as current assets. All other receivables are classified as non-current assets.

(f) Revenue and Other Income

Revenue is recognised when the amount of the revenue can be measured reliably, it is probable that economic benefits associated with the transaction will flow to the entity and specific criteria relating to the type of revenue as noted below, has been satisfied.

Revenue is measured at the fair value of the consideration received or receivable and is presented net of returns, discounts and rebates. For this purpose, deferred consideration is not discounted to present values when recognising revenue.

Interest revenue is recognised using the effective interest method, which for floating rate financial assets is the rate inherent in the instrument. Dividend revenue is recognised when the right to receive a dividend has been established.

Grant and donation income is recognised when the entity obtains control over the funds, which is generally at the time of receipt.

If conditions are attached to the grant that must be satisfied before the association is eligible to receive the contribution, recognition of the grant as revenue will be deferred until those conditions are satisfied.

Other revenue is recognised when the institute is entitled to the funds.

All revenue is stated net of the amount of goods and services tax.

(g) Leases

Leases of PPE, where substantially all the risks and benefits incidental to the ownership of the asset (but not the legal ownership) are transferred to the association, are classified as finance leases.

Finance leases are capitalised by recording an asset and a liability at the lower of the amounts equal to the fair value of the leased property or the present value of the minimum lease payments, including any guaranteed residual values. Lease payments are allocated between the reduction of the lease liability and the lease interest expense for that period.

Leased assets are depreciated on a straight-line basis over the shorter of their estimated useful

lives or the lease term. Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged as expenses in the periods in which they are incurred.

(h) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the

amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.lives or the lease term. Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged as expenses in the periods in which they are incurred.

(h) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.

(i) Financial Assets

Investments in financial assets are initially recognised at cost, which includes transaction costs, and are subsequently measured at fair value, which is equivalent to their market bid price at the end of the reporting period. Movements in fair value are recognised through an equity reserve.

(j) Accounts Payable and Other Payables

Accounts payable and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the association during the reporting period that remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

(k) Provisions

Provisions are recognised when the association has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions are measured at the best estimate of the amounts required to settle the obligation at the end of the reporting period.

(l) Income Tax

Lions Cancer Institute Inc. is exempt from income tax and registered as deductible gift recipient.

	2018 \$	2017 \$
NOTE 2: DEPRECIATION AND AMORTISATION EXPENSES		
Depreciation - plant and equipment	54,915.11	56,619.88
NOTE 3: SHOW ACCOUNT EXPENSES		
Show account expenses	659,924.89	623,629.58
Show account bank fee	897.69	1,129.37
	<u>660,822.58</u>	<u>624,758.95</u>
NOTE 4: OTHER EXPENSES		
Sun Smudge expenses	-	949.75
ANZI 2017	386.65	-
Training	5,180.36	197.14
Corporate Expenses	2,576.95	-
	<u>8,143.96</u>	<u>1,146.89</u>
NOTE 5: RECEIVABLES		
Fuel tax receivable	-	134.00
GST refundable	-	2,462.00
Trade debtors	13,568.00	7,500.00
	<u>13,568.00</u>	<u>10,096.00</u>
NOTE 6: CASH ASSETS		
Westpac # 3738	12,536.34	89,916.03
Cash Reserve Bonus # 635-033	100.00	-
Business cash reserve 8557	97,148.37	10,281.07
SA/NT #620-173	8,095.39	-
Community solution account 0011	92,858.65	122,434.01
Term deposit - short term	-	-
Interest accrued	-	-
	<u>210,738.75</u>	<u>222,631.11</u>
NOTE 7: OTHER ASSETS		
Prepayments	6,860.52	-
Credit Card- other	1,396.95	-
Credit Card - D Mainard	-	7,632.60
Credit Card - C Beauchamp	1,219.52	-
	<u>9,476.99</u>	<u>7,632.60</u>

	2018 \$	2017 \$
NOTE 8: PROPERTY, PLANT AND EQUIPMENT		
UHF Radio	452.73	452.73
Less accumulated depreciation	(452.73)	(452.73)
Photo Finder	24,110.00	24,110.00
Less accumulated depreciation	(24,110.00)	(24,110.00)
Generator	14,200.00	14,200.00
Less accumulated depreciation	(11,160.72)	(9,131.54)
Dermalite 11 multispectral	6,681.82	6,681.82
Less accumulated depreciation	(6,681.82)	(6,681.82)
Screening equipment	12,558.14	3,298.14
Less accumulated depreciation	(2,784.44)	(1,550.68)
Coach 1EFV 432	305,754.62	305,754.62
Less accumulated depreciation	(193,474.74)	(155,255.41)
Molecam	1,813.64	1,813.64
Less accumulated depreciation	(1,813.64)	(1,723.19)
Van 1TNK 399	83,965.46	83,965.46
Less accumulated depreciation	(59,912.72)	(49,417.04)
Notebook computer	559.09	559.09
Less accumulated depreciation	(559.09)	(559.09)
iPhone 4	390.00	390.00
Less accumulated depreciation	(390.00)	(390.00)
Coach 1EFV432 -Sat. phone	4,698.00	4,698.00
Less accumulated depreciation	(3,311.37)	(1,745.53)
Van 1TNK 399 -Sat. phone	2,220.45	2,220.45
Less accumulated depreciation	(1,559.02)	(818.94)
Tvs - Van and Coach	580.87	580.87
Less accumulated depreciation	(470.78)	(277.18)
Lumino Screening Lamps	1,041.67	1,041.67
Less Accumulated Depreciation	<u>(363.36)</u>	<u>(16.17)</u>
	151,982.06	197,637.17
NOTE 9: FINANCIAL ASSETS		
Colonial First State	770,185.87	658,364.19
NOTE10: PAYABLES		
Trade creditors	89,047.68	98,484.75
S/INT Donations	-	2,000.00
	<u>89,047.68</u>	<u>100,484.75</u>


**Associations Incorporation Reform Act 2012
ss 94(2)(b), 97(2)(b) and 100(2)(b)**

Annual statements give true and fair view of financial position and performance
Of Incorporated Association

We, Lion Phil Chinnery and PDG Neil F. Saunders , being members of the board of directors of Lions Cancer Institute Inc. , certify that:

The statements attached to this certificate give a true and fair view of the financial position and performance of Lions Cancer Institute Inc. during and at the end of the financial year of the association ending on 30 June 2018


Chairman


Treasurer

Dated: 21-10-2018

**INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF
Lions Cancer Institute Inc.**

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Lions Cancer Institute Inc. (the association), which comprises the assets and liabilities statement as at 30/06/2018, the income and expenditure statement for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the certification by members of the board of directors on the annual statements giving a true and fair view of the financial position and performance of the association.

In our opinion, the accompanying financial report gives a true and fair view of the financial position of Lions Cancer Institute Inc. as at 30/06/2018 and of its financial performance for the year then ended in accordance with the accounting policies described in Note 1 to the financial statements, and the requirements of The Associations Incorporation Act 2015 (WA).

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the association in accordance with ethical requirements of the Accounting Professional and Ethical Standards Board 's APES 110: *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter - Basis of Accounting

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared to assist the association to meet the requirements of The Associations Incorporation Act 2015 (WA) . As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Responsibilities of the Board of Directors for the Financial Report

The board of directors is responsible for the preparation and fair presentation of the financial report in accordance with the financial reporting requirements of The Associations Incorporation Act 2015 (WA) and for such internal control as the board of directors determines is necessary to enable the preparation and fair presentation of a financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the board of director is responsible for assessing the association' s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the board of directors either intends to liquidate the association or to cease operations, or have no realistic alternative but to do so. The board of directors is responsible for overseeing the association 's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor 's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

- As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the association's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the board of directors.
- Conclude on the appropriateness of the board of directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the association's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the association to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the board of directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Auditax Accountants
Chartered Accountant



Dharam Ghangas
Director

Place: Perth
Dated: 20/10/2018

	2018 \$	2017 \$
INCOME		
Donations - Lions Clubs	42,095.00	24,750.00
Donations- screening unit	9,882.10	4,824.60
Donations- private	2,870.75	655.00
Jesse Martin cash tin	200.00	395.00
Donations- corporate	3,253.80	4,382.28
Karen & Joshua Chinnery scholarship	3,000.00	1,000.00
SA Telemarketing	32,994.59	-
South Australia Set Up	200.00	-
Corporate screening	8,772.73	18,440.91
Distribution - Colonial First State	41,341.96	37,175.03
Franking Credits Refund	2,068.00	-
Fuel tax credits	952.00	862.00
Other income	-	26.59
Raffle income	-	6,000.00
Show account income	816,415.73	778,803.95
Sun Smudge income	1,110.00	930.00
Westpac bank interest	479.69	469.30
Westpac term deposit Interest	-	3,305.01
	965,636.35	882,019.67
EXPENDITURE		
ANZI 2017	386.65	-
Corporate Expenses	2,576.95	-
Office rental	1,130.18	1,830.91
Insurance	4,183.85	4,079.52
Presentation	235.45	300.00
Postage and shipping	321.91	371.16
Bank charges	325.46	236.55
Computer supplies	1,139.19	702.23
Telephone expenses	1,820.12	1,768.03
Accounting and audit	3,581.78	3,016.35
Stationary and printing	3,863.70	6,384.97
Vehicle Storage	3,856.51	4,712.73
Staff amenities	497.91	338.41
Sundry exp	397.92	161.81
Other employer expenses	4,395.32	1,256.73
Fundraising expenses	20.91	1,150.91
Screening expenses	589.44	2,931.18
Screening equipment repairs	177.27	38.64
Screening costs -Coach 1 EFV 432	56.50	214.08

These statements should be read in conjunction with the attached compilation report.

	2018 \$	2017 \$
Screening Costs - Van 1TNK 399	131.01	38.17
Screening - travel and transportation	23,163.26	10,831.84
Screening - advertising	2,651.03	3,434.10
Screening - printing and distribution	1,163.04	179.05
Screening - accommodation costs	22,375.80	12,626.27
Screening - subsistence costs	14,350.35	6,761.31
Show account bank fee	897.69	1,129.37
Show account expenses	659,924.89	623,629.58
Sun Smudge expenses	-	949.75
Training	5,180.36	197.14
Vehicle insurance	6,056.95	6,074.99
Vehicle licensing and transfer	2,414.18	2,197.63
Vehicle - generator maintenance	1,423.80	559.07
Vehicle -generator fuel	723.66	488.75
Vehicle diesel fuel - Hino 1 BUA 284	1,095.25	2,532.20
Vehicle maintenance -Hino 1BUA 284	5,879.49	2,289.92
Vehicle fuel costs- Coach 1EFV 432	5,630.87	2,592.36
Vehicle maintenance - Coach 1EFV 432	17,484.31	24,384.72
Vehicle maintenance - Van 1TNK 399	7,753.36	3,106.39
Vehicle fleet card fees	200.93	11.94
Public relations expenses	1,842.71	130.91
K & J Chinnery scholarship	6,000.00	6,000.00
SA Telemarketing costs	26,395.67	-
South Australia set up-net expenses	1,094.63	769.43
Australian Set up costs	814.24	-
Advisor fees	2,280.02	1,533.77
Depreciation - plant and equipment	54,915.11	56,619.88
Change in net market value of investments	(7,759.74)	(1,150.12)
	<u>893,639.89</u>	<u>797,412.63</u>
SURPLUS FROM ORDINARY ACTIVITIES BEFORE INCOME TAX	<u>71,996.46</u>	<u>84,607.04</u>
Retained surplus at the beginning of the financial year	<u>995,160.06</u>	<u>910,553.02</u>
TOTAL AVAILABLE FOR APPROPRIATION	<u>1,067,156.52</u>	<u>995,160.06</u>

These statements should be read in conjunction with the attached compilation report.

DATE	CLUB	vRECEIPT #
6/07/2017	North Beach LC	2489
17/07/2017	Northampton L.C.	2485
24/07/2017	Booragoon L.C.	2492
24/07/2017	Canning City L.C.	2481
28/07/2017	Serpentine-Jarrahdale	3303
10/08/2017	Pinjarra	2484
10/08/2017	Atwell L.C.	2494
10/08/2017	Stirling Inc. L.C.	2493
10/08/2017	Karratha/Dampier LC	2495
21/08/2017	Carnarvon L.C.	2496
21/08/2017	Kulin L.C.	2497
31/08/2017	Bull Creek L.C.	2499
31/08/2017	Kingsley Woodvale L.C.	2498
31/08/2017	Kojonup L.C.	2500
05/09/2017	Ballajura L.C.	2350
28/09/2017	Northam L.C.	2351
02/11/2017	Albany South Coast L.C.	1234
01/12/2017	Denmark L.C.	1236
15/01/2018	Donation	1238
30/04/2018	Busselton L.C.	2483
30/04/2018	Dunsborough L.C.	3122
30/04/2018	Esperance L.C. 201W2	2463
17/05/2018	Bull Creek	2488
29/05/2018	Port Kennedy	2475
29/05/2018	Armadale-Kelmscott LC 201W2	2468
29/05/2018	Capel L.C.	3459
29/05/2018	Gingin-Chittering L.C. 201W1	2478
29/05/2018	Noranda L.C.	2467
29/05/2018	Whitford L.C.	2466
13/06/2018	Duncraig LC	1791
15/06/2018	Boddington L.C.	1795
15/06/2018	Cowaramup L.C.	2471
15/06/2018	Rockingham L.C.	
15/06/2018	Waroona L.C. 201W2	
22/06/2018	Booragoon L.C.	
22/06/2018	Dongara/Denison L.C. 201W1	
22/06/2018	Kingsley Woodvale L.C.	
22/06/2018	Kojonup L.C.	
22/06/2018	North Beach L.C.	
25/06/2018	Canning City	

Total Donated by Lions Clubs
\$42,095

PDG Garry Irvine
 Mr Alister Turner MBBS FRCS FRACS
 Mr Robert Fitzpatrick MBBS FRCS FRACS
 Mr Barrie Lykke MBBS FRACS FRACS (Retired)
 Professor Kurt Gebauer MBBS FACD
 Dr Lester Cowell MBBS
 Mrs Monika Cowell
 Lion Susan Goddard BA APP. Sc. FRCNA (Retired)
 PDG Colin Beauchamp AM.JP
 PDG RON VAUGHAN (Deceased)
 Mr DON PHILLIPS (Deceased)

DIRECTOR
 PLASTIC SURGEON
 PLASTIC SURGEON
 PLASTIC SURGEON
 PROFESSOR OF DERMATOLOGY
 PRIMARY CARE SKIN CANCER PRACTITIONER
 DERMOGRAPHER
 REGISTERED NURSE
 DERMOGRAPHER



▲ LIONS CLUB OF NORTHAM PRESIDENT, WAYNE MORGAN, HANDING OVER A CHEQUE



30 years of Australian research and development ensures that SunSense sunscreens are for real Australian conditions and real Australian lifestyles. Developed to suit individual needs, SunSense sunscreens not only provide SPF protection, but offer the added benefits of moisturising Vitamin B3. The SunSense range is specifically formulated using high quality ingredients to provide specialised choices for all ages and skin types including sensitive skin and the delicate skin of young children.

Visit www.sunsense.com.au for more information.

All SunSense sunscreens are Australian made in Braeside, Victoria and Australian family owned

Natural Coloured Diamonds

Imagine possessing a unique piece of custom designed Jewellery.



Buying a Diamond and designing a piece of Jewellery around that that Diamond can be an exciting and creative project.



Compassion Diamonds

Contact: Clyde Jones 0438 592 140

www.compassiondiamonds.com.au

CHAIRMAN

Mobile: 0428 420 275

Email: phil.chinnery@lionscancerinstitute.org.au

TREASURER

Telephone: 0418 947 345

Email: treasurer@lionscancerinstitute.org.au

PO Box 2195,
MANDURAH DC, WA 6210